Trump Unveils Massive Drug Price Cuts: New Most-Favored-Nation Deals with Pharma Giants to Lower Costs for Americans
In a bold push to fulfill campaign vows, President Trump unveiled sweeping drug price reforms on December 19, 2025, securing most-favored-nation (MFN) deals with pharma giants like Pfizer and Moderna. The agreements tie U.S. prices to lower international rates, projecting 30-50% cuts on insulin, cancer drugs, and generics—saving Americans $500 billion over a decade.
Trump hailed it as “the biggest win for patients ever,” targeting “Big Pharma rip-offs” amid economic woes. Seniors on Medicare could see immediate relief, with caps at $35/month for insulin echoing Biden-era policies but expanded.
Critics, however, question enforcement: voluntary deals lack teeth, and pharma lobbies warn of innovation stifles. “It’s optics over overhaul,” said Sen. Bernie Sanders (I-VT), pushing for mandatory negotiations.
The move follows marijuana reclassification, positioning Trump as health reformer despite approval dips to 36%. Polls show 75% support lower prices, potentially buoying midterms.
As holidays near, this “gift” aims to counter Epstein fury and inflation gripes. Will it deliver? Pharma stocks dipped, but patients hope for real relief.
